CN117717066A - Embryo preservation solution, cryopreservation method thereof and application of embryo preservation solution in cryopreservation of Babylonia embryos - Google Patents
Embryo preservation solution, cryopreservation method thereof and application of embryo preservation solution in cryopreservation of Babylonia embryos Download PDFInfo
- Publication number
- CN117717066A CN117717066A CN202410155544.9A CN202410155544A CN117717066A CN 117717066 A CN117717066 A CN 117717066A CN 202410155544 A CN202410155544 A CN 202410155544A CN 117717066 A CN117717066 A CN 117717066A
- Authority
- CN
- China
- Prior art keywords
- embryo
- babylonia
- preservation solution
- embryos
- cryopreservation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000606434 Babylonia Species 0.000 title claims abstract description 118
- 239000003761 preservation solution Substances 0.000 title claims abstract description 68
- 210000002257 embryonic structure Anatomy 0.000 title claims abstract description 67
- 238000003890 embryo preservation Methods 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 37
- 238000005138 cryopreservation Methods 0.000 title claims description 21
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims abstract description 34
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 17
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 17
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 17
- 239000000872 buffer Substances 0.000 claims abstract description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 10
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 210000001161 mammalian embryo Anatomy 0.000 claims description 98
- 238000004321 preservation Methods 0.000 claims description 28
- 238000001816 cooling Methods 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 229960004308 acetylcysteine Drugs 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 7
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 claims description 7
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 7
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 7
- 229960000740 enrofloxacin Drugs 0.000 claims description 7
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 7
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- WJEIYVAPNMUNIU-UHFFFAOYSA-N [Na].OC(O)=O Chemical compound [Na].OC(O)=O WJEIYVAPNMUNIU-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- QNEFNFIKZWUAEQ-UHFFFAOYSA-N carbonic acid;potassium Chemical compound [K].OC(O)=O QNEFNFIKZWUAEQ-UHFFFAOYSA-N 0.000 claims description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940053050 neomycin sulfate Drugs 0.000 claims description 2
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 claims description 2
- 229960003053 thiamphenicol Drugs 0.000 claims description 2
- 239000000022 bacteriostatic agent Substances 0.000 claims 2
- 230000004083 survival effect Effects 0.000 abstract description 15
- 238000011161 development Methods 0.000 abstract description 14
- 230000018109 developmental process Effects 0.000 abstract description 14
- 230000012447 hatching Effects 0.000 abstract description 12
- 230000008569 process Effects 0.000 abstract description 8
- 238000011160 research Methods 0.000 abstract description 8
- 230000000052 comparative effect Effects 0.000 description 37
- 238000007710 freezing Methods 0.000 description 22
- 230000008014 freezing Effects 0.000 description 22
- 210000003250 oocyst Anatomy 0.000 description 18
- 238000010257 thawing Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 238000010586 diagram Methods 0.000 description 9
- 235000013601 eggs Nutrition 0.000 description 9
- 241000237858 Gastropoda Species 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 239000013535 sea water Substances 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 210000004081 cilia Anatomy 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000007798 antifreeze agent Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 230000001418 larval effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 229940037003 alum Drugs 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 210000000625 blastula Anatomy 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 239000004576 sand Substances 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 238000004017 vitrification Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 210000001647 gastrula Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000238553 Litopenaeus vannamei Species 0.000 description 2
- 241000237852 Mollusca Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 238000002194 freeze distillation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 210000004508 polar body Anatomy 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000223600 Alternaria Species 0.000 description 1
- 241000965254 Apostichopus japonicus Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002528 anti-freeze Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002267 larvicidal agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- -1 salt ion Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention discloses a preservation solution for embryos. The embryo preservation solution comprises, in 1L of solvent: 1.0 to 4.0g/L acetamide, 0.01 to 0.04g/L N-acetylcysteine, 0.04 to 0.06g/L polyvinyl alcohol, 0.02 to 0.06g/L bacteriostat, 0.3 to 0.6g/L buffer and 15 to 30g/L carbon source. The embryo preservation solution can effectively preserve the Babylonia embryos, fix the states of the Babylonia embryos, delay the biological development process of the embryos, better improve the survival rate and the hatching rate of the thawed Babylonia embryos, and meet the requirements of research and cultivation of the Babylonia.
Description
Technical Field
The invention belongs to the technical field of Babylonia culture, and particularly relates to embryo preservation solution, a freezing preservation method thereof and application thereof in the freezing preservation of Babylonia embryos.
Background
Babylonia commonly known as Bulgaria and Bulgaria, belongs to the phylum Mollusca (Mollusca), class Gastropoda (Gastropoda), class Alternaria (Prosobranchia), class Neopaptogra (Neopatropoda), family Bucciidae (Bucciidae), genus Babylonia (Babylonia). The Babylonia has delicious meat quality and rich nutrition, is deeply favored by consumers, has wide market prospect, expands the culture scale and the culture area of the Babylonia year by year, and rapidly develops the artificial culture of the Babylonia.
Since the advent of the cryopreservation technology, the technology has become one of the indispensable research methods in the field of natural science and has been widely adopted. With the improvement of living standard and the development of medical technology, the cryopreservation technology is not only important for the cryopreservation of human germ cells (sperm, oocyte), gonadal tissues and the like; but also has important significance for resource protection, proliferation and breeding, breeding improvement and biological basic research of aquatic animals.
The most commonly used method of cryopreservation at present is the vitrification method, which is generally operated as follows: freezing protective agent with high concentration is solidified in ultralow temperature environment by gradual cooling to form irregular vitrification-like solid, normal molecular and ion distribution in liquid state is preserved, and thus, the protection effect can be achieved when vitrification occurs in cells. After the preserved cells are dehydrated to a certain degree in the cryoprotectant, endogenous cytoplasmic macromolecules such as proteins are caused to permeate into the cells, and the cryoprotectant is concentrated, so that the cells are protected in severe rapid cooling.
At present, the low-temperature preservation researches of aquatic animal sperms and egg cells at home and abroad are more, but the preservation of embryos is less, and the preservation technology of Babylonia embryos is not yet reported. Patent CN109819977A discloses a freezing preservation method of embryos of Litopenaeus vannamei, which comprises the steps of firstly carrying out freezing resistance treatment on embryos of Litopenaeus vannamei hatched for 8 hours by using a freezing resistance liquid, and then carrying out freezing treatment on the embryos by adopting a slow freezing method or a fast freezing method. Wherein the antifreeze fluid comprises glycerol, seawater, auxiliary agents (methanol, ethylene glycol or glycerol), bovine serum albumin, polysucrose, etc. Patent CN116034992a discloses a low-temperature preservation solution for stichopus japonicus sperm, the low-temperature preservation solution consists of a solution, fetal calf serum and a green streptomycin mixed solution, and the solution is isotonic buffer solution or natural seawater.
However, the preservation solutions are used for vitrification cryopreservation of the Babylonia embryos, so that the Babylonia embryos are easy to deform, and the thawed Babylonia embryos are broken; in addition, the easy dissolution of infectious bacteria affects the subsequent normal development and survival of the Babylonia embryos, and the preservation requirement of the Babylonia embryos cannot be met, namely the existing vitrification solution is not suitable for the freezing preservation of the Babylonia embryos. Therefore, how to provide a preservation solution and a preservation method suitable for the Babylonia embryo is a technical problem to be solved.
Disclosure of Invention
Aiming at the prior art problems, the primary aim of the invention is to provide an embryo preservation solution, which can effectively preserve the Babylonia embryos, fix the states of the Babylonia embryos, delay the biological development process of the embryos, better improve the survival rate and the hatching rate of the frozen Babylonia embryos and meet the requirements of Babylonia research and cultivation.
The second object of the present invention is to provide a method for preparing an embryo preservation solution.
The third object of the invention is to provide an application of embryo preservation solution in the freezing preservation of Babylonia embryos.
The fourth object of the present invention is to provide a method for cryopreserving an embryo of Babylonia.
The fifth object of the invention is to provide an application of the cryopreservation method of the Babylonia embryo in the cryopreservation of the Babylonia embryo.
In order to achieve the above object, the present invention is realized by the following technical scheme:
an embryo preservation solution comprising, in 1L solvent: 1.0 to 4.0g/L acetamide, 0.01 to 0.04g/L N-acetylcysteine, 0.04 to 0.06g/L polyvinyl alcohol, 0.02 to 0.06g/L bacteriostat, 0.3 to 0.6g/L buffer and 15 to 30g/L carbon source.
The invention provides a preservation solution for embryos, which is prepared by selecting acetamide as an antifreeze agent, and the inventor finds that compared with other antifreeze agents, the acetamide can more effectively protect the Babylonia embryos, reduce the freezing point of the external liquid of the Babylonia embryos, reduce the formation of ice crystals outside the Babylonia embryos, and promote the outflow of water in the Babylonia embryos, so that the formation of ice crystals in the Babylonia embryos is finally reduced.
Further, the inventor finds that the N-acetylcysteine can remove free radicals generated in the metabolic process of the Babylonia embryos, maintain the oxidation-reduction environment in cells and prevent apoptosis in the cryopreservation process compared with other antioxidants by taking the N-acetylcysteine as an antioxidant and taking the polyvinyl alcohol as a stabilizer through research. The polyvinyl alcohol can maintain the activity of the Babylonia embryo, has good adaptability to the Babylonia embryo, and can improve the permeation and pressure resistance of the embryo.
Furthermore, the embryo preservation solution also contains an antibacterial agent, has a good antibacterial effect, can prevent the Babylonia embryo from infecting bacteria, and has low toxicity. The buffer is used as osmotic buffer, can maintain the salt ion concentration of tissue cell osmotic pressure and maintain the pH stability of physiological environment, provides proper osmotic pressure and pH value, maintains the activity of embryo, and improves the permeation-resistant effect of embryo. The carbon source can be used as an energy substrate of the embryo, and can provide energy to maintain the lowest physiological metabolism condition of the embryo and maintain long-term preservation of the embryo.
Under the synergistic effect of the specific combination, the biological development process of the Babylonia embryo is greatly delayed, the cell activity of the Babylonia embryo is maintained, the cell metabolism is reduced, the cell death or apoptosis is reduced, and the Babylonia embryo can play the original function of the embryo after thawing and restore the development of the embryo.
Preferably, the embryo preservation solution comprises, in 1L solvent: 2.0 to 3.0g/L acetamide, 0.02 to 0.03g/L N-acetylcysteine, 0.05 to 0.06g/L polyvinyl alcohol, 0.03 to 0.05g/L bacteriostat, 0.4 to 0.5g/L buffer and 20 to 25g/L carbon source.
Preferably, the bacteriostat is selected from one or more of enrofloxacin, neomycin sulfate and thiamphenicol.
Preferably, the buffer is selected from one or more of potassium dihydrogen phosphate, sodium dihydrogen carbonate, and potassium dihydrogen carbonate.
Preferably, the carbon source is selected from one or more of trehalose, glucose, fructose.
Further, the invention provides a preparation method of embryo preservation solution, which comprises the steps of mixing acetamide, N-acetylcysteine, polyvinyl alcohol, a bacteriostat, a buffer, a carbon source and a solvent, and uniformly stirring to obtain the embryo preservation solution.
Further, the invention claims an application of embryo preservation solution in the cryopreservation of Babylonia embryos.
Further, the invention discloses a freeze preservation method of the Babylonia embryo, which comprises the steps of pre-treating the Babylonia embryo to remove embryo emulsion, and then gradually cooling and freeze-preserving the Babylonia embryo by adopting the embryo preservation solution.
Preferably, the volume ratio of the Babylonia embryo to the embryo preservation solution is 1: (2-3).
Preferably, the pretreatment is: mixing Babylonia embryo with Alumen solution, removing embryo emulsion, and cleaning. More specifically, the volume concentration of alum in the alum solution is 0.3-0.5%. The inventor finds that when the oocyst membrane of the Babylonia is broken, endosperm liquid in the oocyst membrane easily causes the Babylonia embryo to infect bacteria, and alum solution can play a role in removing endosperm liquid, so that the infection of the Babylonia embryo is reduced.
Preferably, in some embodiments, the step-wise cooling is performed by:
balancing the mixed solution of the Babylonia embryo and the preservation solution at 20 ℃, 15 ℃, 10 ℃, 5 ℃ and 0 ℃ for 5-6 minutes in sequence, wherein the cooling speed is 3 ℃/minute;
at the temperature of between 0 and 60 ℃ below zero, respectively balancing for 7 to 12 minutes at the three time points of between 10 ℃ below zero, 20 ℃ below zero and 60 ℃ below zero, wherein the cooling speed is 2 ℃/min;
at the stage of-60 ℃ to-100 ℃, balancing for 10-15 minutes at the two time points of-80 ℃ and-100 ℃, cooling at the speed of 1 ℃/min, and rapidly placing the mixture into liquid nitrogen for preservation when the temperature is reduced to-100 ℃.
Preferably, the Babylonia embryo is one or more of a cleavage stage embryo, a blastula stage embryo, or a primordial stage embryo.
Further, the invention requests an application of the cryopreservation method of the Babylonia embryo in the cryopreservation of the Babylonia embryo.
Compared with the prior art, the invention has the following beneficial effects:
(1) Aiming at the characteristics of the Babylonia embryos, the invention adopts a specific embryo preservation solution combination to reduce the freezing point of the embryo external solution, reduce the formation of ice crystals in the embryos, effectively inhibit bacterial growth, provide proper osmotic pressure and pH value, maintain the activity of the Babylonia embryos, reduce the metabolism of cells and reduce cell death or apoptosis. The embryo preservation solution combination provided by the invention can fix the state of the Babylonia embryo, delay the biological development process of the embryo, and better improve the survival rate and the hatching rate of the Babylonia embryo after freezing preservation.
(2) The embryo preservation solution combination provided by the invention has low toxicity to the Babylonia embryos, and the preserved Babylonia embryos have high survival rate by matching with a progressive freezing method.
(3) The preservation method provided by the invention prolongs the extracapsular preservation time of the Babylonia embryo, has simple preservation conditions, can exert the original functions of cells after thawing, continues the development of the embryo, is suitable for scientific research and production, and can observe the development state of the embryo or be used for experiments such as embryo in situ hybridization and the like.
Drawings
FIG. 1 is a schematic diagram showing the process of collecting the oocysts of Babylonia and culturing the embryo of Babylonia in a nursery pond after thawing, and forming young snails by adhesion metamorphosis in example 5. Wherein a in fig. 1 is a schematic diagram of female screw mating oviposition in example 5; FIG. 1B is a schematic view of example 5 before and after removal of sand, wherein the upper side of the diagram is the oocysts carrying the sand, and the lower side is the oocysts after removal of the sand; FIG. 1C is a schematic diagram showing the situation of the Babylonia embryo in example 5 after thawing and placing the embryo in a nursery pond when the embryo develops into a larvae of the face plate; d in FIG. 1 is a schematic diagram of the young snails obtained by thawing the Babylonia embryos and culturing them in a nursery pond and then subjecting them to adhesion transformation in example 5.
FIG. 2 is a schematic diagram showing the stages of normal development of the embryo of Babylonia in example 5 before freezing and after thawing, and a schematic diagram showing the lysis of infectious bacteria after thawing of the embryo of Babylonia in comparative example 1. Wherein, A in figure 2 is the fertilized egg stage of the Babylonia embryo before freezing; b in FIG. 2 is the stage of releasing the first diode after thawing the Babylonia embryo; c in FIG. 2 is the 2-cell phase of the thawed Babylonia embryo; d in fig. 2 is 4 cell phase after thawing of the Babylonia embryo; e in FIG. 2 is the multicellular stage of the Babylonia embryo after thawing; f in FIG. 2 is the blastula stage of the Dongfeng spiral embryo after thawing; g in fig. 2 is the primordial stage of the thawed eastern whelk embryo; h in FIG. 2 is a schematic diagram showing the dissolution of infectious bacteria after thawing of Babylonia embryos without embryo preservation solution in comparative example 1.
Detailed Description
The invention is further illustrated in the following drawings and specific examples, which are not intended to limit the invention in any way. Unless specifically stated otherwise, the reagents, methods and apparatus employed in the present invention are those conventional in the art.
The phrase "cleavage stage" refers to: the size of the embryo in oocysts is generally 256-280 microns multiplied by 224-240 microns in the development stage from fertilized eggs to multicellular, the embryo in oocysts is yellow brown and is in a sphere or oval shape, and the embryo is suspended in a viscous embryo emulsion, and the first polar body, the second polar body and cell division can occur successively in the period, and the embryo is continuously divided until reaching multicellular.
The phrase "blastula" refers to: forming a white transparent belt above the animal polar cell division of the embryo in the eastern conch oocyst; the plant superthin cells become smaller as the cells divide, the blastomere becomes smaller, the embryo morphology changes from flat to round, and the embryo enters into blastula stage.
The phrase "primordial" refers to: the embryo in the eastern wind snail oocyst is changed into ellipse from nearly circular shape, and has endoderm and gastrula, and has cilia and gastrula hole to form gastrula, and the embryo body can rotate in the oocyst by the swing of cilia.
The phrase "larvicide" refers to: the embryo in the oocyst of Babylonia develops into a film-forming inner larva, and the larva in the stage grows with cilia roof, cilia ring, kidney primordium, pericardium, shell gland, balance capsule, hindfoot, small-leaved lemma, larval shell and the like.
The phrase "in-membranous disc larval stage" refers to: the larvae in the eastern wind snail oocysts grow into two symmetrically connected subelliptic faceplates, a pair of black and sessile eyespots appear on the heads, the larvae shells grow into spiral shapes, esophagus and rectum are formed, and most of space of the embryo body is occupied by the yolk pieces.
The phrase "early panel larval stage" refers to: two residual yolk pieces are obviously seen in the Babylonia larvae, and two faceplates are oval, bilateral symmetry and dense-edged cilia development period.
The phrase "mid-shelf larval stage" refers to: the egg yolk of the Babylonia larvae disappears, and the larvae grow with obvious characteristics of eyes, forefeet, primary shells, a pair of antennae and the like.
The phrase "late shelf-life" refers to: the head of the Babylonia larva grows with kish, water pipe and gill wire which are obviously differentiated, and 1-2 rows of reddish brown pigment spots appear on the spiral layer.
The phrase "young snail" refers to: the palace pan of the Babylonia larvae is atrophied, cilia fall off, and the floating is changed into crawling.
Example 1 preparation of embryo preservation solution
1L of disinfection seawater is prepared, 3.0g/L of acetamide, 0.05g/L of enrofloxacin, 0.5g/L of monopotassium phosphate, 0.03g/L N-acetylcysteine, 25g/L of trehalose and 0.06g/L of polyvinyl alcohol are sequentially added, and the embryo preservation solution is prepared after uniform stirring.
Example 2 preparation of embryo preservation solution
1L of disinfection seawater is prepared, 2.0g/L of acetamide, 0.03g/L of enrofloxacin, 0.4g/L of monopotassium phosphate, 0.02g/L N-acetylcysteine, 20g/L of trehalose and 0.05g/L of polyvinyl alcohol are sequentially added, and the embryo preservation solution is prepared after uniform stirring.
Example 3 preparation of embryo preservation solution
1L of disinfection seawater is prepared, 1.0g/L of acetamide, 0.02g/L of enrofloxacin, 0.3g/L of monopotassium phosphate, 0.01g/L N-acetylcysteine, 15g/L of trehalose and 0.04g/L of polyvinyl alcohol are sequentially added, and the embryo preservation solution is prepared after uniform stirring.
Example 4 preparation of embryo preservation solution
Preparing 1L of disinfection seawater, sequentially adding 4.0g/L acetamide, 0.06g/L enrofloxacin, 0.6g/L monopotassium phosphate, 0.04g/L N-acetylcysteine, 30g/L trehalose and 0.06g/L polyvinyl alcohol, and uniformly stirring to prepare the embryo preservation solution.
Example 5A cryopreservation method of Babylonia embryo
(1) As shown in A in figure 1, regulating temperature (25-30 ℃) and feeding biological bait (oyster) to perform gonad ripening and mating spawning on Babylonia maculata, and collecting the generated Babylonia egg bag;
(2) As shown in B in figure 1, hanging the Babylonia egg bag stained with sand on the water upper layer by using a porous plastic frame, wherein the ratio of the area of the egg bag to the area of the plastic frame is less than 1/3, suspending the egg bag upwards on the water surface, and cutting off an egg handle by using scissors;
(3) Cutting along the edge of the egg bag with scissors, pouring out the Babylonia embryo, filtering and collecting the Babylonia embryo with a filter screen, washing off endosperm liquid of the embryo with alum solution with volume concentration of 0.3%, and cleaning with clean sterile seawater;
(4) The Babylonia embryo cleaned in the step (3) and the embryo preservation solution prepared in the example 1 are mixed according to the volume ratio of 1:3, placing the frozen tube into a program cooling instrument for cooling step by step, and balancing at 20 ℃, 15 ℃, 10 ℃, 5 ℃ and 0 ℃ for 5 minutes at a cooling speed of 3 ℃/min; at the temperature of between 0 and 60 ℃ below zero, respectively balancing for 8 minutes at the three time points of between 10 ℃ below zero, 20 ℃ below zero and 60 ℃ below zero, wherein the cooling speed is 2 ℃/min; at the stage of-60 ℃ to-100 ℃, balancing for 12 minutes at the two time points of-80 ℃ and-100 ℃, cooling at the speed of 1 ℃/min, and rapidly placing the frozen storage tube into liquid nitrogen for storage when the temperature of the frozen storage tube is reduced to-100 ℃.
Example 6 cryopreservation method of Babylonia embryo
The difference between this embodiment and embodiment 1 is that: embryo preservation solution prepared in example 2 was used.
Example 7A method for cryopreserving Dongfeng spiral embryo
The difference between this embodiment and embodiment 1 is that: embryo preservation solution prepared in example 3 was used.
Example 8A cryopreservation method of Babylonia embryo
The difference between this embodiment and embodiment 1 is that: embryo preservation solution prepared in example 4 was used.
Comparative example 1
The difference between this comparative example and example 5 is that: without using the preservation solution prepared in example 1, the Babylonia embryos were directly placed in a freezing tube and gradually cooled in a program cooling instrument.
Comparative example 2
The difference between this comparative example and example 5 is that: embryo preservation solutions prepared in example 1 without acetamide were used.
Comparative example 3
The difference between this comparative example and example 5 is that: embryo preservation solutions prepared in example 1 without enrofloxacin were used.
Comparative example 4
The difference between this comparative example and example 5 is that: embryo preservation solutions prepared in example 1 without potassium dihydrogen phosphate were used.
Comparative example 5
The difference between this comparative example and example 5 is that: embryo preservation solution prepared in example 1 without N-acetylcysteine was used.
Comparative example 6
The difference between this comparative example and example 5 is that: embryo preservation solution prepared in example 1 without trehalose was used.
Comparative example 7
The difference between this comparative example and example 5 is that: embryo preservation solutions prepared in example 1 without polyvinyl alcohol were used.
Comparative example 8
The difference between this comparative example and example 5 is that: preservation solution prepared in example 1 without N-acetylcysteine and polyvinyl alcohol.
Comparative example 9
The difference between this comparative example and example 5 is that: acetamide is replaced with dimethyl sulfoxide using antifreeze agents conventional in the art.
Comparative example 10
The difference between this comparative example and example 5 is that: acetamide is replaced with ethylene glycol using antifreeze agents conventional in the art.
Comparative example 11
The difference between this comparative example and example 5 is that: the N-acetylcysteine is replaced with vitamin C using antioxidants conventional in the art.
Comparative example 12
The difference between this comparative example and example 5 is that: the polyvinyl alcohol is replaced with sodium bicarbonate using stabilizers conventional in the art.
Comparative example 13
The difference between this comparative example and example 5 is that: the temperature is reduced step by step without adopting a program temperature reducing instrument, and the mixture is directly put into liquid nitrogen for freezing.
Test example 1
(1) In example 5, embryos were frozen out and thawed by 7 days of liquid nitrogen. Babylonia embryos are placed into a seedling raising pond for cultivation after successfully entering early washbasin larva stage, as shown in C in figure 1. After cultivation, early larvae develop sequentially through mid-stage and late-stage larvae, and eventually become deformed to land to form young snails, as shown by D in fig. 1. The embryo development process is shown as a in fig. 2 to G in fig. 2. H in FIG. 2 is a schematic diagram showing dissolution of infectious bacteria after thawing of the Babylonia embryo without addition of embryo preservation solution in comparative example 1, and as shown in H in FIG. 2, dissolution of the Babylonia embryo infectious bacteria occurs and preservation fails.
From the above, the embryo preservation solution provided by the invention can fix the state of the Babylonia embryo and delay the biological development process of the embryo. The toxicity to the Babylonia embryo is small, the preservation time outside the capsule of the Babylonia embryo is prolonged by matching with a progressive freezing method, the preservation condition is simple and convenient, the original functions of cells can be exerted after thawing, and the development of the embryo is continued.
(2) Survival and hatchability tests: randomly extracting 3 oocysts from the total number of oocysts for detecting the number of the embryo, observing under a microscope, recording the number of the oocyst embryos of each embryo, calculating to obtain an average value, and multiplying the average value by the total number of the oocysts to obtain the initial embryo number. The embryo's development through different stages to early panel larval stages was considered successful. Hatching rate is the number of developed trochophore larvae over the number of initial embryos; the embryo is taken and placed under a microscope to observe the integrity degree of the embryo body, whether deformation and fracture exist or not, and the survival rate is the number of the preserved complete embryo compared with the number of the initial embryo.
Initial embryo number = average number of embryo per oocyst x total number of oocysts.
Hatchability = number of basilar larva stages/number of initial embryos x 100%.
Survival = number of intact embryos/number of initial embryos x 100%.
The Babylonia embryos were frozen and stored for 24 hours and thawed according to the method for freezing and storing Babylonia embryos described in examples and comparative examples, the thawed embryos were hatched for 48 hours, the hatching results were observed, the survival rate and the hatching rate of the embryos were counted, and the final test data results are shown in Table 1.
TABLE 1
The data show that under the synergistic effect of the components of the embryo preservation solution, the Babylonia embryos can be effectively preserved, the cell activity of the embryos is maintained, the survival rate and the hatching rate of the Babylonia embryos are better improved, and the requirements of Babylonia research and culture are met. The survival rate of the freeze-preserved Babylonia embryos is more than 59 percent, and the hatching rate is more than 47 percent. Further preferably, the survival rate is > 63% and the hatching rate is > 54%.
As is clear from example 5 and comparative example 1, the Babylonia embryos were not preserved with the embryo preservation solution, and all the Babylonia embryos died after thawing.
As is clear from examples 5, 2, 9 and 10, when the embryo preservation solution does not contain acetamide, the Babylonia embryos all die. Compared with other antifreeze agents in the field, the acetamide has more excellent preservation effect on the Babylonia embryos, and the survival rate and the hatching rate of the Babylonia embryos after freezing preservation are obviously improved.
From example 5, comparative example 3, comparative example 4 and comparative example 6, it is known that it is difficult to achieve the technical effects of the present invention when the antibacterial agent, the buffer and the carbon source are not contained in the embryo preservation solution.
As is clear from examples 5, comparative examples 5 and comparative example 11, it is difficult to achieve the technical effects of the present invention when N-acetylcysteine is not contained in the embryo preservation solution. Compared with other antioxidants in the field, the N-acetylcysteine has more excellent preservation effect on the Babylonia embryos, and the survival rate and the hatching rate of the Babylonia embryos after freezing preservation are obviously improved.
As is clear from examples 5, 7 and 12, it is difficult to achieve the technical effects of the present invention when the embryo preservation solution does not contain polyvinyl alcohol. Compared with other stabilizers in the field, the polyvinyl alcohol has more excellent preservation effect on the Babylonia embryos, and the survival rate and the hatching rate of the Babylonia embryos after freezing preservation are obviously improved.
As can be seen from example 5 and comparative example 13, the stepwise cooling is critical for preservation of Babylonia embryos.
The foregoing examples are illustrative only and serve to explain some features of the method of the invention. The claims that follow are intended to claim the broadest possible scope as conceivable and the embodiments presented herein are demonstrated for the applicant's true test results. It is, therefore, not the intention of the applicant that the appended claims be limited by the choice of examples illustrating the features of the invention. Some numerical ranges used in the claims also include sub-ranges within which variations in these ranges should also be construed as being covered by the appended claims where possible.
Claims (10)
1. An embryo preservation solution, characterized in that the embryo preservation solution comprises, in 1L of solvent: 1.0 to 4.0g/L acetamide, 0.01 to 0.04g/L N-acetylcysteine, 0.04 to 0.06g/L polyvinyl alcohol, 0.02 to 0.06g/L bacteriostat, 0.3 to 0.6g/L buffer and 15 to 30g/L carbon source.
2. The embryo preservation solution of claim 1 wherein the bacteriostatic agent is selected from one or more of enrofloxacin, neomycin sulfate, thiamphenicol.
3. The embryo preservation solution of claim 1 wherein the buffer is selected from one or more of potassium dihydrogen phosphate, sodium dihydrogen carbonate, potassium dihydrogen carbonate.
4. The embryo preservation solution of claim 1 wherein the carbon source is selected from one or more of trehalose, glucose, fructose.
5. The method for producing an embryo preservation solution according to any one of claims 1 to 4, wherein acetamide, N-acetylcysteine, polyvinyl alcohol, a bacteriostatic agent, a buffer, a carbon source and a solvent are mixed and stirred uniformly to obtain the embryo preservation solution.
6. Use of the embryo preservation solution according to any one of claims 1 to 4 for cryopreservation of Babylonia embryos.
7. A method for cryopreserving a Babylonia embryo, comprising pretreating the Babylonia embryo to remove embryo emulsion, and subsequently gradually cooling and cryopreserving the Babylonia embryo by using the embryo preservation solution according to any one of claims 1 to 4.
8. The cryopreservation method of claim 7 wherein the volume ratio of Babylonia embryos to embryo preservation solution is 1: (2-3).
9. The cryopreservation method of claim 7 wherein the pretreatment is: mixing Babylonia embryo with Alumen solution, removing embryo emulsion, and cleaning.
10. The method of claim 7, wherein the step-wise cooling is performed by:
sequentially balancing the mixed solution of the Babylonia embryo and the embryo preservation solution at 20 ℃, 15 ℃, 10 ℃, 5 ℃ and 0 ℃ for 5-6 minutes, wherein the cooling speed is 3 ℃/min;
at the temperature of between 0 and 60 ℃ below zero, respectively balancing for 7 to 12 minutes at the three time points of between 10 ℃ below zero, 20 ℃ below zero and 60 ℃ below zero, wherein the cooling speed is 2 ℃/min;
at the stage of-60 ℃ to-100 ℃, balancing for 10-15 minutes at the two time points of-80 ℃ and-100 ℃, cooling at the speed of 1 ℃/min, and when the temperature is reduced to-100 ℃, placing the mixture into liquid nitrogen for preservation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410155544.9A CN117717066B (en) | 2024-02-04 | 2024-02-04 | Embryo preservation solution, cryopreservation method thereof and application of embryo preservation solution in cryopreservation of Babylonia embryos |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410155544.9A CN117717066B (en) | 2024-02-04 | 2024-02-04 | Embryo preservation solution, cryopreservation method thereof and application of embryo preservation solution in cryopreservation of Babylonia embryos |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117717066A true CN117717066A (en) | 2024-03-19 |
CN117717066B CN117717066B (en) | 2024-04-26 |
Family
ID=90209138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410155544.9A Active CN117717066B (en) | 2024-02-04 | 2024-02-04 | Embryo preservation solution, cryopreservation method thereof and application of embryo preservation solution in cryopreservation of Babylonia embryos |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117717066B (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101451120A (en) * | 2008-12-31 | 2009-06-10 | 厦门大学 | Abalone blood cell anticoagulation protecting agent and preparation method thereof |
CN102550541A (en) * | 2010-12-23 | 2012-07-11 | 潘峰 | Organ vitrification freezing and preserving fluid |
CN102648708A (en) * | 2011-02-25 | 2012-08-29 | 深圳华大方舟生物技术有限公司 | Freezing liquid for embryo or cells and application thereof |
CN111587876A (en) * | 2020-05-25 | 2020-08-28 | 大连海洋大学 | Rapid vitrification cryopreservation and recovery method for sea urchin intermedium embryo |
CN112167245A (en) * | 2020-10-27 | 2021-01-05 | 深圳华大基因细胞科技有限责任公司 | Protective agents for cell preservation |
AU2020221966A1 (en) * | 2019-02-13 | 2021-09-30 | Takeda Pharmaceutical Company Limited | Cryopreservation of stem cells |
CN115052479A (en) * | 2019-12-10 | 2022-09-13 | 耶达研究及发展有限公司 | Cryopreserved insects and methods of producing same |
CN116814525A (en) * | 2023-06-09 | 2023-09-29 | 广东海洋大学 | Culture medium for culturing Babylonia embryos and method for culturing Babylonia embryos outside capsules |
-
2024
- 2024-02-04 CN CN202410155544.9A patent/CN117717066B/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101451120A (en) * | 2008-12-31 | 2009-06-10 | 厦门大学 | Abalone blood cell anticoagulation protecting agent and preparation method thereof |
CN102550541A (en) * | 2010-12-23 | 2012-07-11 | 潘峰 | Organ vitrification freezing and preserving fluid |
CN102648708A (en) * | 2011-02-25 | 2012-08-29 | 深圳华大方舟生物技术有限公司 | Freezing liquid for embryo or cells and application thereof |
AU2020221966A1 (en) * | 2019-02-13 | 2021-09-30 | Takeda Pharmaceutical Company Limited | Cryopreservation of stem cells |
CN115052479A (en) * | 2019-12-10 | 2022-09-13 | 耶达研究及发展有限公司 | Cryopreserved insects and methods of producing same |
CN111587876A (en) * | 2020-05-25 | 2020-08-28 | 大连海洋大学 | Rapid vitrification cryopreservation and recovery method for sea urchin intermedium embryo |
CN112167245A (en) * | 2020-10-27 | 2021-01-05 | 深圳华大基因细胞科技有限责任公司 | Protective agents for cell preservation |
CN116814525A (en) * | 2023-06-09 | 2023-09-29 | 广东海洋大学 | Culture medium for culturing Babylonia embryos and method for culturing Babylonia embryos outside capsules |
Also Published As
Publication number | Publication date |
---|---|
CN117717066B (en) | 2024-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113273567B (en) | Low-temperature preservation liquid for patinopecten yessoensis sperms and preservation and use method | |
CN112741078B (en) | Hexagrammos otakii sperm productive cryopreservation method | |
Samarin et al. | In vitro storage of unfertilized eggs of the Eurasian perch and its effect on egg viability rates and the occurrence of larval malformations | |
WO2021012763A1 (en) | Method for ultra-low temperature cryopreservation of sea cucumber sperm | |
Glogowski et al. | Activity of aspartate aminotransferase and acid phosphatase in cryopreserved trout sperm | |
Hatipoğlu et al. | Fertilizing ability of short-term preserved spermatozoa Abant trout (Salmo trutta abanticus T, 1954) | |
KR20170130404A (en) | Methods of maintaining ovaries of marine fishes, adjusting the culture medium, and producing eggs or embryos of marine fishes | |
Colombo et al. | Artificial fertilization and induction of triploidy and meiogynogenesis in the European sea bass, Dicentrarchus labrax L. | |
CN114258911A (en) | Cryopreservation solution and cryopreservation method for sparus latus sperms | |
Gil et al. | Effects of cryoprotectants and diluents on the cryopreservation of spermatozoa from far eastern catfish, Silurus asotus | |
Kusuda et al. | Cryopreservation of chum salmon blastomeres by the straw method | |
CN103960182B (en) | A kind ofly apply the method that shrimp ovum cultured in vitro sets up Exopalaemon carinicauda family | |
KR101847707B1 (en) | Method of Cryopreservation of Sperm in Abalone and Spat Production from them | |
CN117717066B (en) | Embryo preservation solution, cryopreservation method thereof and application of embryo preservation solution in cryopreservation of Babylonia embryos | |
Lahnsteiner et al. | An efficient method for cryopreservation of testicular sperm from the Northern pike, Esox lucius L. | |
Stoss et al. | Preservation of fish gametes | |
Goffredo et al. | Hermaphroditism and brooding in the solitary coral Balanophyllia europaea (Cnidaria, Anthozoa, Scleractinia) | |
Hamaratogˇlu et al. | Cryopreservation of starfish oocytes | |
Paes et al. | Post-cooling survival, growth and deformity rates in zebrafish embryos (Danio rerio) | |
JP6983452B2 (en) | Ultra-low temperature cryopreservation method for sea cucumber sperm | |
US4834024A (en) | Inducing polyploidy in oysters | |
CN112293407A (en) | Method for programmed cryopreservation of ovarian tissues | |
CN112293411B (en) | Low-temperature preservation liquid and preservation method for sperms of echinococcus intermedius | |
Moore et al. | Preparation, cryopreservation, and growth of cells prepared from the green turtle (Chelonia mydas) | |
CN113767896B (en) | Bovine in vitro fertilization embryo vitrification freezing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |